Nicobrevin is a proprietary product containing quinine, menthyl valerate, camphor and eucalyptus oil marketed as an aid to smoking cessation. No randomised trials with long-term follow-up of smoking status were identified, so there was no evidence to assess efficacy.
Vollständige Zusammenfassung lesen
Nicobrevin is a proprietary product marketed as an aid to smoking cessation. It contains quinine, menthyl valerate, camphor and eucalyptus oil.
Zielsetzungen
The objective of this review was to assess the effects of Nicobrevin on long-term smoking cessation
Suchstrategie
We searched the Cochrane Tobacco Addiction Group trials register. Most recent search was January 2009.
Auswahlkriterien
Randomized trials comparing Nicobrevin to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow up.
Datensammlung und ‐analyse
Data were sought on the outcome, method of randomisation, and completeness of follow up.
Hauptergebnisse
We identified no trials meeting the full inclusion criteria including long-term follow-up.
Schlussfolgerungen der Autoren
There is no evidence available from long-term trials that Nicobrevin can aid smoking cessation.
